“Our aim is
to foster new business via collaboration”
Läufer, CEO, Corvay GmbH, Germany
As a part of the initiative of Germany´s Federal Ministry of
Education and Research to internationally market German research
competence, a group of delegates were present at the recently concluded
Bangalore BIO 2009, India’s largest biotechnology business
conference. On the sidelines of the three-day long event, Dr Albrecht
Läufer, CEO of Corvay GmbH, a German life sciences consultancy
and management services company, who also represented BioRegioN, a
German state Niedersachsen’s life science initiative, at
Bangalore BIO 2009. Excerpts from the intervie
Would you tell us
more about Corvay and the services offered by it?
Corvay provides expert consultancy and management services in life
sciences, to customers in Germany and other countries, with a special
focus on the Middle East and Asian countries, viz; India, China,
Indonesia, Japan and Singapore. The company offers services
like developing business strategies and writing business plans for
start-up companies and interim management.
Corvay also acts as the management office of the ‘Life
Science Network Niedersachsen – BioRegioN’, on
behalf of the Ministry of Economics, Labor and Transport of
Germany´s state of Niedersachsen.
What were your
expectations from Bangalore BIO 2009? What does BioRegioN has on offer?
At Bangalore BIO 2009, our aim was to exhibit the research potential
and market the life sciences sector of Niedersachsen. I was campaigning
for BioRegioN that offers a platform for networking for all the
partners of ‘Life Science Niedersachsen goes India’
initiative. We established very good contacts with several Indian life
sciences leaders, scientists and with people interested in project
management for the commercialization of their products.
BioRegioN is a very strong biotechnology cluster linking 150 small and
medium size enterprises, large companies, 20 universities and academic
research institutions. The purpose is to foster innovation and new
business through collaboration. Recently, under the umbrella of the
research marketing campaign of Germany’s Federal Ministry of
Science and Education, BioRegioN has presented its innovative strengths
in all fields of biotechnology. In India, more attention is given to
infection research, bio-IT, plant biotechnology, bioenergy
and waste management. We are coordinating talks between Indian partners
and members of BioRegioN, which we expect to result in collaboration
contracts. We are also organizing an Indo-German conference,
BioTechnica, Europe’s largest biotech event on October 7-8,
2009, in Hannover, Germany. As part of the conference, Indian
companies will get a chance to visit biotechnology firms and
institutions in Germany.
What are the primary
aims of the ‘Life Science Niedersachsen goes India’
The campaign seeks to establish R&D cooperations between life
science institutes and companies in India in the fields of diagnostics
for cancer, arteriosclerosis and infectious diseases, protein research,
biological databases, knowledge tools and softwares. Furthermore, the
exchange of qualified employees and scientists between India and
Niedersachsen shall be encouraged with their participation in infection
research programs and resources management programs.
How encouraging is
the regulatory environment in Asia and the Middle East?
Regulatory systems are different and complex in each country.
Authorities in Asia have little experience with new substances and rely
very much on licenses under the US or European drug administrations.
Biotechnology is gaining importance in many Asian and Middle East
countries, new products will be introduced as a result and there is a
need for proper regulatory attention and proper IP protection as well.
Corvay’s business initiatives in India?
Our company is active in India since several years, and I’m
impressed by the growth in the biotech sector. Many experienced NRI
scientists and businessmen who are returning to India are investing in
the country. Also, Indian pharmaceutical and vaccine companies are
venturing into biotechnology, so I see India on the right track to
become a powerhouse in biotechnology. Medical need and the purchasing
power in India are increasing. Indian market is very well connected
with other Asian markets such as Singapore, Thailand, Malaysia,
Indonesia and China. So, I feel India is certainly a good and safe
place to set your shop.